Navigation Links
7UP Gives Consumers a New Reason to Fall in Love - New Cherry 7UP Antioxidant
Date:2/2/2009

Cherry 7UP Antioxidant Allows Consumers to Cherry Pick Their Antioxidant

PLANO, Texas, Feb. 2 /PRNewswire-FirstCall/ -- Just in time for the perfect Valentine's Day toast, the 7UP brand is romancing consumers with its latest creation - Cherry 7UP Antioxidant. The pink-hued, crisp and refreshing beverage combines the delicious flavor of 7UP with a hint of cherry flavor and the bonus of antioxidant Vitamin E.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080507/LAW016LOGO)

"Cherry 7UP Antioxidant gives consumers a refreshing way to enjoy more of the antioxidants they are looking for," said Ian Norton, brand manager of marketing for 7UP. "People want to fall in love with beverages that taste great and provide a fun way to get benefits. And that's exactly what Cherry 7UP Antioxidant delivers."

The new Cherry 7UP Antioxidant includes 10 percent of the recommended daily intake of Vitamin E per eight ounce serving. Cherry 7UP Antioxidant is available now in both regular and diet versions and, like all 7UP products, is 100 percent naturally flavored and caffeine free.

The nationwide launch of Cherry 7UP Antioxidant will be supported by an integrated marketing campaign featuring TV and print advertisements. Consumers can also visit www.7UP.com and download a coupon for $1 off a 12-pack of Cherry 7UP Antioxidant.

Cherry 7UP Antioxidant is available nationwide everywhere 7UP products are sold. The new flavor will be available in 12-pack, 2 liter and 20-ounce sizes, as well in 8-ounce trial cans. More information on Cherry 7UP Antioxidant can be found at www.7UP.com.

About 7UP

7UP is a leading brand in the beverage portfolio of Dr Pepper Snapple Group, In
'/>"/>

SOURCE Dr Pepper Snapple Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. President Obama Gives the Unborn at Least a 24 Hour Reprieve, Postpones $441 Million Bailout of International Abortions, Says Family Research Council
2. Former Johnson & Johnson Executive Gives Big Voice to Small Companies
3. Growth in the Functional Food Sector Gives a Hearty Boost to the Heart Health Ingredients Market
4. CVS/pharmacy Teams Up with Access Hollywood for an Award Season Gifting Suite That Gives Back
5. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
6. NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
7. Sandias microencapsulation project gives local entrepreneur warm glow
8. Celebrity Event Gives Local Non-Profits a Reason to be Thankful
9. Anthem Blue Cross Gives the Gift of Health to California
10. VIDEO from Medialink and PUIG USA: Antonio Banderas Blue Seduction for Women Gives Back for the Holidays
11. The SCOOTER Store Gives Power Wheelchair to Good Samaritan Critically Injured Trying to Save Others
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 1Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 2Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 3NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 1NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4